Background: The monocyte-derived cytokine, tumor necrosis factor a (TNFa), is essential for host immunity,
INTRODUCTION
Tumor necrosis factor a (TNFa) is one of the important immunologic mediators generated by cells of the monocyte/macrophage lineage and has been shown to have significant effects on host immunity in bacterial and parasitic infections (1) . Tuberculosis is a chronic mycobacterial infection (of macrophages and monocytes) in which TNFa is characteristically produced. TNFa is present in the pleural effusions of patients infected with Mycobacterium tuberculosis, and monocytes isolated from patients with active dis-ease and systemic symptoms release elevated amounts of TNFa into the culture supernatant in response to stimuli (2) (3) (4) . In vitro, mycobacterial preparations have been shown to induce TNFa production by human monocytes (5) . TNFa is essential for granuloma formation (6, 7) , which is intimately associated with resistance against mycobacteria (8) .
While production of TNFa is essential for host immunity, overproduction of this cytokine may have serious pathologic consequences. In experimental animals, high levels of TNFa induce fever by direct action on the hypothalamus (1), and long-term administration of this cytokine causes marked losses of fat and muscle cells or cachexia (9) . Elevated levels of TNFa produced in pulmonary tuberculosis may be responsible for many of the pathologic symptoms of the disease, including fevers, weakness, fatigue, night sweats, lung necrosis, and progressive weight loss (10) .
The control of these pathologic effects of excess TNFa production has received increasing attention. In animal models of gram-negative sepsis, administration of either antibodies directed against TNFa or pharmaceutical agents that suppress TNFa production, leads to reduced fevers, less wasting, and significantly decreased mortality (11) . One drug, thalidomide (a-N-phthalimidoglutarimide), has recently been shown to suppress TNFa production by human monocytes in vitro (12, 13) and to normalize elevated levels of serum TNFa in vivo (12, 14) . The inhibitory activity of thalidomide is due to a selective destabilization of the TNFa mRNA (15) ; thalidomide selectively suppresses TNFa production in vitro without directly affecting the levels of other cytokines such as interleukin-1 (IL-1), IL-6, and granulocyte/macrophage-colony stimulating factor (GM-CSF) (13) .
Since thalidomide inhibits but does not abolish TNFa production, thalidomide therapy might reduce the toxicities linked with overproduction of the cytokine, without interfering with its important role(s) in host immunity. Recent studies have shown that thalidomide has prompt and dramatic effects when given to leprosy patients with erythema nodosum leprosum (ENL), including the elimination of the lesions, a decrease in inflammation, and general enhancement of patient well-being. These studies suggest that thalidomide may play a therapeutic role in tuberculosis patients, where much of the pathology may be TNFa mediated, but where a normal immune response and granuloma formation is important in the control of the infection.
In order to determine the effect of thalidomide on TNFa levels and whether thalidomide treatment is associated with any untoward side effects, including drug toxicity or suppression of immune reactivity, we have conducted a twopart placebo-controlled pilot study of thalidomide in patients with active tuberculosis. The results of our study indicate that thalidomide reduces TNFa production by peripheral blood mononuclear cells (PBMCs) in patients receiving anti-tuberculosis therapy without any adverse effects. Furthermore, although all patients showed the normal expected response to antituberculosis therapy, only patients treated with thalidomide demonstrated significant increased weight gain during the study period.
MATERIALS AND METHODS Study Drug
Thalidomide (CG-217) was provided in 100-mg tablets (Lot 204 and 206) by Grunenthal GMBH (Aachen, Germany). Placebo tablets were also provided by Grunenthal GMBH (Aachen, Germany). Results are means ± one standard deviation (SD) evaluated before (pre), during (mid), and 5 days after (post) 14-day treatment cycles with 300 mg/day of thalidomide or placebo (see Table 1 In vivo. Patients treated with thalidomide had significantly enhanced serum IFNy levels after 7 days of the first cycle of thalidomide treatment (Fig. 1) . The serum IFNy levels returned to baseline upon discontinuation of drug. In contrast, there was no increase in serum IFNy levels in patients treated with placebo ( Fig. 1) .
Study Design
In vitro. When PBMCs isolated from patients were stimulated with PPD, IFNy was released into the culture medium (Fig. 1) . Similar results Table 1 ). No significant changes were observed.
were observed when PBMCs from patients were stimulated with BCG ( and waned when thalidomide treatment ended, a group of patients from Group II was treated with a second 14-day cycle of thalidomide after a 7-day washout period. When PBMCs were obtained from patients during the second cycle of thalidomide treatment and stimulated with LPS, the effect on TNFa levels was reproduced (Fig. 3) .
To test whether the thalidomide-induced reduction in TNFa-producing capacity of PBMC was correlated with lower circulating TNFa levels in the patients, serum TNFa levels were measured during two consecutive 14-day cycles of thalidomide treatment (with washout periods between treatment cycles). When serum from patients was assayed for TNFa during repeated cycles of thalidomide treatment, a decrease in serum TNFa was observed at the midpoint of each thalidomide treatment (Fig. 3) . In addition, mRNA was isolated from unstimulated PBMCs of patients receiving the sequential cycles of thalidomide treatment. Analysis of levels from unstimulated PBMC during thalidomide treatment, showed decreases in the number of copies of TNFa mRNA, mirroring the decrease in serum TNFa levels (Fig. 3) . 103 5a-I PBMC to release TNFa, it was important to determine whether the production of other inflammatory cytokines, such as IL-1, was similarly affected. We therefore examined the plasma and PBMC for production and release of IL-1. IL-1 was not detected in either plasma or serum from patients receiving thalidomide. However, IL-1 release by LPS-stimulated PBMC in vitro was reduced by thalidomide treatment similar to the reduction in TNFa levels (Fig. 3) . IL-1 levels rebounded after cessation of thalidomide treatment, but when thalidomide treatment was resumed, IL-1 levels again were reduced at the treatment midpoint (Fig. 3) . No significant effect on IL-I mRNA levels expressed by freshly tested PBMC was observed in response to multiple cycles of thalidomide treatment (Table 6 ). In vitro LPS induced release of TNFa (top) and IL-1 (bottom) from PBMC. Serum TNFa levels and PBMC TNFa mRNA levels (middle). Results are means ± one SEM for samples obtained from five patients treated with two 14-day cycles of thalidomide (Material and Methods). TNFa mRNA levels and LPS induced TNFa were significantly lower as compared with the pretreatment levels (p < 0.008 and p < 0.005 respectively). (Fig. 4) . Some of the patients receiving placebo also gained weight, but to a lesser extent than the thalidomide treated patients. Both HIV-1-and HIV-1+ patients gained weight similarly (not shown). Upon withdrawal of thalidomide at 14 days, a reversal or cessation of weight gain was observed (Fig. 4) . In order to evaluate the reproducibility and persistance of the effect of thalidomide on weight gain, six of the Group II (New York only) patients were treated with sequential cycles of thalidomide or placebo in the following manner. Three patients were treated with a 14-day cycle of thalidomide, followed by a 7-day washout period, and then retreatment with thalidomide (Fig. 5) . Three patients were treated with a cycle of thalidomide, followed by a washout period, followed by treatment with placebo (Fig. 5) . Finally, two patients were treated with placebo during the first 14-day cycle, followed by a washout period, and then followed by thalidomide treatment (Fig. 5) . The rate of weight gain was significantly higher while patients were receiving thalidomide, whether or not they had been treated with thalidomide in previous cycles. Moreover, the rate of weight gain was much lower while patients were on placebo or during the washout period. If patients were treated in the first cycle with thalidomide and then received placebo during the second treatment cycle, they stopped gaining weight at the accelerated rate, but these patients did not lose the weight gained during the thalidomide treatment. As a group, patients on placebo gained less weight than patients on thalidomide. This occurred despite maintaining a relatively constant caloric intake before, during, and after thalidomide and/or placebo treatment (Fig. 6) . Thus, the weight gain during thalidomide treatment did not appear to be dependent on a change in caloric intake.
DISCUSSION
TNFa is an important regulatory cytokine of host response to bacterial and parasitic infections (1) . A delicate balance must be maintained: enough TNFa must be produced to stimulate host immunity, but overproduction of this cytokine may have extremely deleterious effects. Increasing attention has therefore focussed on thalidomide, a therapeutic agent that appears to down-regulate TNFa overproduction without completely suppressing it (12) (13) (14) . To determine whether thalidomide might affect TNFa production and the subsequent disease course in tuberculosis, we carried out a two-part placebo-controlled pilot study of thalidomide treatment in patients with tuberculosis and wasting. Our observations showed that thalidomide at a dose of 300 mg per day for 14 days was well tolerated with minimal side effects. No adverse clinical manifestations were noted in either patients infected with M. tuberculosis alone or patients with dual infections of tuberculosis and HIV-1.
For thalidomide to be clinically useful in controlling the consequences of excessive TNFa production during a chronic infectious process, it should not adversely affect other parameters of host immunity. Therefore, the possible effects of thalidomide treatment on host immunity in tuberculosis were investigated in a number of ways. First, delayed type hypersensitivity was assessed in each patient during the study. Our results show that the response to PPD was not diminished during or after administration of thalidomide, as quantitated by skin test responsiveness (Table 2) . On the contrary, there was evidence of enhanced reactivity. That is, HIV-1-and HIV-1+ patients who were initially nonresponsive to mycobacterial antigen, developed skin test responsiveness during the administration of thalidomide. This was not observed in placebo-treated patients, suggesting that the observed reactivity was not due to a booster effect of repeated PPD administration.
Administration of thalidomide did not cause any significant changes in total leukocyte count or differential cell count (Table 3) , nor was there any significant effect on lymphocyte subset distribution in either HIV-1 + or HIV-1 patients. In addition, when PBMCs were isolated from patients during the course of thalidomide treatment, there was no change in the proliferative capacity of the PBMCs following in vitro stimulation with antigens (Table 4) . Thalidomide did not suppress cell-mediated immunological responses in vitro during the treatment cycle.
The effect of thalidomide treatment on cytokine production was evaluated in all patients during the study. Thalidomide treatment resulted in increased levels of IFNy secretion both in vivo, in the serum of patients, and in vitro by PBMCs stimulated with mycobacterial preparations (Fig. 1) . This effect was observed in both HIV-1 + and HIV-1-patients. The apparent immunostimulatory effect of thalidomide was limited to the treatment cycle, and when thalidomide therapy ceased, the effect waned (Fig. 1) . The effect of thalidomide treatment on TNFa production, both in vitro and in vivo, was pronounced. PBMCs were isolated from patients during the study and then stimulated in vitro, with a variety of agonists. Thalidomide treatment of tuberculosis patients was clearly associated with a reduced production of TNFa in vitro by stimulated PBMCs (Fig. 2) . The effect of thalidomide treatment on TNFa levels was transitory, and cytokine levels returned to baseline when thalidomide treatment ended. However, when patients were treated with a second 14-day cycle of thalidomide, following a 7-day washout period, the effect on TNFa was repeated and TNFa levels in vitro again declined (Fig. 3) . These results showed that continuous thalidomide treatment was necessary to maintain the reduction in PBMC capacity to produce TNFa.
Simultaneously, we investigated the effect of thalidomide treatment on TNFa production in the patients. It had previously been noted that circulating TNFa levels are notoriously difficult to detect (16) . In our study, serum or plasma TNFa was not detected by the Endogen ELISA kit (Fig. 3) . This is a possible explanation for why cells from these patients release less of this cytokine in vitro in response to agonists. We had previously shown that a short thalidomide pulse in vitro to PBMCs stimulated with LPS inhibited TNFa without affecting levels of IL-I production (13) . In the present study, the relatively long cycle of thalidomide administration in vivo had no significant effect on serum IL-I or IL-I mRNA levels. However, thalidomide treatment in vivo did cause a reduction in IL-I release by LPS stimulated PBMCs in vitro (Fig.  3) . These apparently contradictory effects may be due to the sensitivity of PBMC IL-I production to TNFa levels, which are in turn, modulated by the duration of thalidomide treatment in vivo.
All patients in this study gained weight during treatment with thalidomide. While some of the patients treated with MDT and placebo also gained weight, the weight gain of patients treated with thalidomide was significantly greater than that of the placebo-treated group. After the cessation of thalidomide treatment, some patients lost some weight while other ceased to gain weight (Figs. 4 and 5 ). These observations suggest that thalidomide could be used clinically to accelerate weight gain during anti-tuberculosis therapy. In this study, weight gain was not a consequence of increased caloric intake, since there was no significant difference in this parameter between thalidomide and placebo treatment. Some of the thalidomide induced weight gain persisted for at least 4 weeks after the end of thalidomide treatment (Fig. 5) , suggesting that the weight gain was not due merely to transient fluid retention, nor was it due solely to MDT, since placebo-treated patients did not gain as much weight. However, measurement of total body and/or lean body mass are required to conclusively demonstrate the nature of the weight gain during thalidomide treatment. The results presented here suggest that thalidomide may exert a metabolic effect, perhaps mediated through TNFa levels. The nature of this potential metabolic change is being investigated in ongoing studies.
The results of our present study indicate strongly that thalidomide reduces TNFa production in both uncomplicated tuberculosis and tuberculosis associated with HIV-1 infection. The decrease in TNFa production was not associated with any clinical deterioration or negative effects on host immunity. How treatment with thalidomide impacts on the cytokine regulatory circuit and results in reduced TNFa production is as yet unknown. Our results suggest that cachexia may, at least in part, be mediated by chronic production of TNFa. Thalidomide therapy might thus be instrumental in reversing the debilitating symptoms of M. tuberculosis infection as well as in another syndrome with associated cachexia, the acquired immunodeficiency syndrome (17) . Also, the reduction in TNFa induced by thalidomide may have profound effects on other physiologic pathways that are modulated by cytokine levels. For example, we have recently shown that thalidomide induced reduction in TNFa is associated with a reduction in activation of latent HIV-1 in vitro (18) . The mechanism of this effect and its potential effect on clinical course is currently under investigation in our laboratory.
